Dr. Marcia Eisenberg, Labcorp Diagnostics Chief Scientific Officer, named to Fierce Healthcare’s 2021 Women of Influence

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 1, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Marcia Eisenberg , Ph.D., chief scientific officer of Labcorp Diagnostics , was recognized by Fierce Healthcare as one of its “2021 Women of Influence.” The award honors leaders who are defining the future of health care, have tangibly influenced the industry during the prior year and have a history of guiding others in their careers.

Labcorp announces 2021 third quarter results

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 28, 2021-- Labcorp (NYSE: LH), a leading life sciences company, today announced results for the third quarter ended September 30, 2021 , and raised full-year guidance.

Decision Support: Building a clinical rules engine with the human touch

I began my career in a clinical laboratory that provided automated interpretations as part of our specialty test results based on clinical guidelines. We learned that many physicians' questions could be answered preemptively through these laboratory insights. For example, test results could include clinical information to help manage patients with kidney stones, offering insights on causes and potential treatments options. After Labcorp acquired that laboratory, we began looking for ways to expand and enhance this program.

Pillar Biosciences to collaborate with Labcorp on precision genomic cancer testing using next-generation sequencing

Natick, Mass., Oct. 14, 2021 — Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics company, today announced that it has entered into an agreement with Labcorp (NYSE: LH), a leading global life sciences company, to provide genomic testing for people with cancer.

GeneCentric Therapeutics collaborates with Labcorp to develop novel RNA-based oncology diagnostics

DURHAM, N.C. – Oct. 12, 2021 — GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced a new strategic collaboration with Labcorp, a leading global life sciences company, to develop and commercialize new RNA-based gene signatures as diagnostics for people with cancer.    

BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients

Lexington, MA – September 20, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and Labcorp Drug Development to advance a new diagnostic approach to select immunoparalyzed sepsis patients that could benefit most from Leukine (sargramostim).  Through advancement of a Laboratory Developed Test (LDT) for monocyte HLA-DR, Partner Therapeutics will be able to identify sepsis patients exhibiting an immune suppressed, or immunoparalyzed (IP) state and clinically evaluate Leukine as a study therapy in these individuals. The ability to identify patients with IP sepsis enables a precision medicine approach to maximize clinical benefit from immune boosting study therapy with Leukine.